Scholarlink

Background <p>The progression and metastasis of breast cancer patients are regulated by genetics and epigenetics. Circular RNA (circRNA) plays a pivotal role in modulating the advancement of tumors. The study aimed to explore the clinical performance and regulatory role of hsa-circVIM in breast cancer and its modulatory effect on tamoxifen resistance in hormone receptor (HR) positive breast cancer cells.</p> Methods <p>RT-qPCR was performed to detect hsa-circVIM expression in breast cancer tissues and cells.CCK-8 assay, Transwell assay, and flow cytometric analyses were performed to evaluate the effects of hsa-circVIM on cellular activities in breast cancer cells and TAM sensitivity in MCF7/TR cells. Bioinformatic analyses were conducted to make function and pathway enrichment analyses.</p> Results <p>hsa-circVIM expression was raised in breast cancer and predicted unsatisfactory overall survival outcomes. Silencing of hsa-circVIM suppressed cell viability, and migration capacities, while simultaneously enhancing TAM sensitivity and inducing apoptosis of HR-positive breast cancer cells by targeting miR-1294.</p> Conclusion <p>Elevated hsa-circVIM expression in breast cancer suggested its potential as a prognostic biomarker. hsa-circVIM functions as both a cancer-promoting molecule and a regulator of TAM responsiveness in HR-positive breast cancer cells by regulating miR-1294 expression. Therefore, hsa-circVIM serves as a potent biomarker for prognosis, plays a promoting role in breast cancer progression, and may offer a therapeutic avenue to overcome TAM resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hsa-circVIM regulates breast cancer tumor progression and tamoxifen sensitivity by sponging miR-1294 in hormone receptor-positive breast cancer cells

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月8日

查看全文
  • Ying Chen,
  • Zhenhua Zhang,
  • Xue Luo,
  • Meini Cen,
  • Peng Dai,
  • Xiaoyan Zhu

摘要

Background

The progression and metastasis of breast cancer patients are regulated by genetics and epigenetics. Circular RNA (circRNA) plays a pivotal role in modulating the advancement of tumors. The study aimed to explore the clinical performance and regulatory role of hsa-circVIM in breast cancer and its modulatory effect on tamoxifen resistance in hormone receptor (HR) positive breast cancer cells.

Methods

RT-qPCR was performed to detect hsa-circVIM expression in breast cancer tissues and cells.CCK-8 assay, Transwell assay, and flow cytometric analyses were performed to evaluate the effects of hsa-circVIM on cellular activities in breast cancer cells and TAM sensitivity in MCF7/TR cells. Bioinformatic analyses were conducted to make function and pathway enrichment analyses.

Results

hsa-circVIM expression was raised in breast cancer and predicted unsatisfactory overall survival outcomes. Silencing of hsa-circVIM suppressed cell viability, and migration capacities, while simultaneously enhancing TAM sensitivity and inducing apoptosis of HR-positive breast cancer cells by targeting miR-1294.

Conclusion

Elevated hsa-circVIM expression in breast cancer suggested its potential as a prognostic biomarker. hsa-circVIM functions as both a cancer-promoting molecule and a regulator of TAM responsiveness in HR-positive breast cancer cells by regulating miR-1294 expression. Therefore, hsa-circVIM serves as a potent biomarker for prognosis, plays a promoting role in breast cancer progression, and may offer a therapeutic avenue to overcome TAM resistance.